Corporate News

2024

Statement re: Silicon Valley Bank

13 March 2023

Oxford, UK. GENinCode Plc (AIM: GENI) is aware of media reports indicating the closure of Silicon Valley Bank (“SVB”). The Company does not hold any cash at SVB and does not have a banking relationship with SVB. 

For more information visit www.genincode.com

 

Enquiries:

GENinCode Plc www.genincode.com or via Walbrook PR
Matthew Walls, CEO  
Paul Foulger, CFO
 
Stifel Nicolaus Europe Limited (Nomad and Joint Broker) Tel: +44 (0)20 7710 7600
Alex Price / Ben Maddison / Richard Short
 
Cenkos Securities Plc (Joint Broker)
 
Tel: +44 (0)20 7397 8900
Giles Balleny
Dale Bellis / Michael Johnson (Sales)
 
Walbrook PR Limited
Anna Dunphy / Paul McManus / Louis Ashe-Jepson
 
Tel: 020 7933 8780 or [email protected]

 

About GENinCode:

GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.

GENinCode operates business units in the UK, Europe through GENinCode S.L.U, and in the United States through GENinCode U.S. Inc.

GENinCode tests and technology provide physicians and patients with globally leading preventative care and treatment strategies. GENinCode invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to prevent cardiovascular disease.

2023

Statement re: Silicon Valley Bank

13 March 2023

Oxford, UK. GENinCode Plc (AIM: GENI) is aware of media reports indicating the closure of Silicon Valley Bank (“SVB”). The Company does not hold any cash at SVB and does not have a banking relationship with SVB. 

For more information visit www.genincode.com

 

Enquiries:

GENinCode Plc www.genincode.com or via Walbrook PR
Matthew Walls, CEO  
Paul Foulger, CFO
 
Stifel Nicolaus Europe Limited (Nomad and Joint Broker) Tel: +44 (0)20 7710 7600
Alex Price / Ben Maddison / Richard Short
 
Cenkos Securities Plc (Joint Broker)
 
Tel: +44 (0)20 7397 8900
Giles Balleny
Dale Bellis / Michael Johnson (Sales)
 
Walbrook PR Limited
Anna Dunphy / Paul McManus / Louis Ashe-Jepson
 
Tel: 020 7933 8780 or [email protected]

 

About GENinCode:

GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.

GENinCode operates business units in the UK, Europe through GENinCode S.L.U, and in the United States through GENinCode U.S. Inc.

GENinCode tests and technology provide physicians and patients with globally leading preventative care and treatment strategies. GENinCode invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to prevent cardiovascular disease.

2022

Statement re: Silicon Valley Bank

13 March 2023

Oxford, UK. GENinCode Plc (AIM: GENI) is aware of media reports indicating the closure of Silicon Valley Bank (“SVB”). The Company does not hold any cash at SVB and does not have a banking relationship with SVB. 

For more information visit www.genincode.com

 

Enquiries:

GENinCode Plc www.genincode.com or via Walbrook PR
Matthew Walls, CEO  
Paul Foulger, CFO
 
Stifel Nicolaus Europe Limited (Nomad and Joint Broker) Tel: +44 (0)20 7710 7600
Alex Price / Ben Maddison / Richard Short
 
Cenkos Securities Plc (Joint Broker)
 
Tel: +44 (0)20 7397 8900
Giles Balleny
Dale Bellis / Michael Johnson (Sales)
 
Walbrook PR Limited
Anna Dunphy / Paul McManus / Louis Ashe-Jepson
 
Tel: 020 7933 8780 or [email protected]

 

About GENinCode:

GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.

GENinCode operates business units in the UK, Europe through GENinCode S.L.U, and in the United States through GENinCode U.S. Inc.

GENinCode tests and technology provide physicians and patients with globally leading preventative care and treatment strategies. GENinCode invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to prevent cardiovascular disease.

2021

Statement re: Silicon Valley Bank

13 March 2023

Oxford, UK. GENinCode Plc (AIM: GENI) is aware of media reports indicating the closure of Silicon Valley Bank (“SVB”). The Company does not hold any cash at SVB and does not have a banking relationship with SVB. 

For more information visit www.genincode.com

 

Enquiries:

GENinCode Plc www.genincode.com or via Walbrook PR
Matthew Walls, CEO  
Paul Foulger, CFO
 
Stifel Nicolaus Europe Limited (Nomad and Joint Broker) Tel: +44 (0)20 7710 7600
Alex Price / Ben Maddison / Richard Short
 
Cenkos Securities Plc (Joint Broker)
 
Tel: +44 (0)20 7397 8900
Giles Balleny
Dale Bellis / Michael Johnson (Sales)
 
Walbrook PR Limited
Anna Dunphy / Paul McManus / Louis Ashe-Jepson
 
Tel: 020 7933 8780 or [email protected]

 

About GENinCode:

GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.

GENinCode operates business units in the UK, Europe through GENinCode S.L.U, and in the United States through GENinCode U.S. Inc.

GENinCode tests and technology provide physicians and patients with globally leading preventative care and treatment strategies. GENinCode invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to prevent cardiovascular disease.